Once-monthly minodronic acid filed for approval in Japan
This article was originally published in Scrip
Executive Summary
Astellas and local partner Ono have filed for the Japanese approval of a once-monthly formulation of the oral bisphosphonate, minodronic acid hydrate, for the treatment of osteoporosis.